<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="472">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420314</url>
  </required_header>
  <id_info>
    <org_study_id>201412760</org_study_id>
    <secondary_id>3P30CA086862</secondary_id>
    <nct_id>NCT02420314</nct_id>
  </id_info>
  <brief_title>Pharmacological Ascorbate for Lung Cancer</brief_title>
  <official_title>A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care
      treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive
      high-dose ascorbate in addition to the standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment for non-small cell lung cancer (NSCLC) involves a combined therapy of
      paclitaxel and carboplatin. These drugs are administered once every 21 days. This study adds
      high dose ascorbic acid (75g per infusion) twice per week for up to 4 cycles of therapy.

      Participants will:

        -  receive high doses of intravenous (IV) ascorbate two times a week during each 3 week
           chemotherapy.

        -  have blood samples drawn to measure blood ascorbate levels once every 21 days

      The active therapy portion of this study lasts for 4 months. After that is completed,
      participants will go back to standard therapy for their cancer. Participants will continue
      to have life-long follow-up for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>every 2 months for up to 5 years post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>From cycle 1, day 1, to documented disease progression in CT imaging as described by RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>every 2 months for up to 5 years post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time (in days) it takes for disease to progress as defined by RECIST criteria. Timeframe will be from cycle 1, day 1 to date of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>every 2 months for up to 5 years post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time, measured in months, from cycle 1 day 1 until date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Frequency</measure>
    <time_frame>monthly for up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Categorize and quantify using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4 from cycle 1 day 1 through 1 month post-infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Ascorbate, paclitaxel, carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel, administered once per cycle (3 weeks) Carboplatin, administered once per cycle (3 weeks) Pharmacological ascorbate (ascorbic acid) infusions, 2 times per week for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered intravenously (IV)
Prescribed at 200 mg/m2 (standard dose)
Given once every 21 days (i.e., one cycle)
Up to 4 cycles are administered depending on disease response</description>
    <arm_group_label>Ascorbate, paclitaxel, carboplatin</arm_group_label>
    <other_name>Nov-Onxol</other_name>
    <other_name>Onxol</other_name>
    <other_name>Paclitaxel Novaplus</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered intravenously (IV)
Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)
Given once every 21 days (i.e., one cycle)
Up to 4 cycles are administered depending on disease response</description>
    <arm_group_label>Ascorbate, paclitaxel, carboplatin</arm_group_label>
    <other_name>Amerinet Choice Carboplatin</other_name>
    <other_name>NovaPlus CARBOplatin</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin NovaPlus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Administered intravenously (IV)
75g per infusion
Two infusions per week
1 cycle is 3 weeks
given up to 4 cycles
may be given while chemotherapy if delayed due to low counts</description>
    <arm_group_label>Ascorbate, paclitaxel, carboplatin</arm_group_label>
    <other_name>Pharmacological ascorbate</other_name>
    <other_name>Vitamin C</other_name>
    <other_name>Ascorbate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed stage IIIB or IV non -small cell lung cancer. The potential
             participant must not have received first-line cytotoxic therapy. First line EGFR
             inhibitors or ALK inhibitors are allowed if there was progression on therapy.

          -  CNS metastasis is allowed if the metastasis is treated and there are no signs of
             progression following treatment. The potential participant must be off steroids for
             at least 3 days and be stable.

          -  ECOG performance status of at least 2

          -  absolute neutrophil count (ANC) of at least 1500 cells per mm³

          -  platelet count of at least 100,000 cells per mm³

          -  hemoglobin of at least 8 g/dL

          -  creatinine no greater than 1.5 mg/dL

          -  total bilirubin no greater than 1.5 mg/dL

          -  ALT within 3 times the institutional upper limit of normal

          -  AST within 3 times the institutional upper limit of normal

          -  the participant must tolerate a 15g ascorbate test infusion (screening dose)

          -  the participant must not be pregnant, be willing to have a pregnancy test done if
             deemed necessary, and be willing to use adequate birth control during the study

        Exclusion Criteria:

          -  known EGFR or ALK gene abnormalities if the participant has not yet tried EGFR or ALK
             inhibitor therapies

          -  active hemoptysis within 1 week of screening (more than 1/2 teaspoon of blood per
             day)

          -  actively receiving insulin at the time of ascorbate infusion

          -  G6PD deficiency

          -  leptomeningeal disease

          -  potential participants cannot be on the following drugs: flecainide, methadone,
             amphetamines, quinidine, or chlorpropamide.

          -  prior invasive malignancies (except for non-melanomatous skin cancers or carcinoma in
             situ of the cervix or bladder) unless disease free for at least 5 years

          -  potential participants may not enroll in, or be actively receiving treatment from, a
             therapeutic clinical trial. Observational studies (including imaging studies) are
             acceptable.

          -  uncontrolled intercurrent illness including, but not limited to, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
             psychiatric illness / social situations that would limit compliance with study
             requirements

          -  known HIV positive individuals cannot be enrolled in this trial because high-dose
             ascorbate is a known CYP450 3A4 inducer, which results in lower serum levels of
             antiretroviral agents
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J. Cullen, MD, FACS</last_name>
    <role>Study Director</role>
    <affiliation>The University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Furqan, M.B., B.S.</last_name>
    <phone>(319) 356-1527</phone>
    <email>muhammad-furqan@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bryan Allen, MD, PhD</last_name>
    <phone>(319) 356-3693</phone>
    <email>bryan-allen@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Furqan, M.B., B.S.</last_name>
      <phone>319-356-1527</phone>
      <email>muhammad-furqan@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bryan Allen, MD, PhD</last_name>
      <phone>(319) 356-3693</phone>
      <email>bryan-allen@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel K Berg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taher Abu Hejleh, M.B., B.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Garry R Buettner, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zita Sibenaller, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brett Wagner, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kalpaj Parekh, M.B., B.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian J. Smith, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Bell, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Schall, R.N., B.S.N</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin Kauffman, R.N.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kellie Bodeker, MSHS, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 17, 2016</lastchanged_date>
  <firstreceived_date>April 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Muhammad Furqan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Ascorbate</keyword>
  <keyword>Ascorbic acid</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
